Agenus (AGEN) : Zacks Investment Research ranks Agenus (AGEN) as 2, which is a Buy recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 4 research analysts is 1, which indicates as a Strong Buy.
Agenus (AGEN) : 3 Wall Street analysts covering Agenus (AGEN) believe that the average level the stock could reach for the short term is $8. The maximum price target given is $10 and the minimum target for short term is around $7, hence the standard deviation is calculated at $1.73.
Shares of Agenus Inc. rose by 1.68% in the last five trading days and 27.64% for the last 4 weeks. Agenus Inc. is up 59.63% in the last 3-month period. Year-to-Date the stock performance stands at 33.26%. Agenus (NASDAQ:AGEN): On Tuesdays trading session , Opening price of the stock was $6.12 with an intraday high of $6.16. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $6.03. However, the stock managed to close at $6.05, a loss of 0.49% for the day. On the previous day, the stock had closed at $6.08. The total traded volume of the day was 854,276 shares.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).